Cardiology Conference-CVC 2026

Myocarditis and inflammatory heart disease are conditions characterized by inflammation of the heart muscle, often as a result of viral infections, autoimmune mechanisms, or systemic inflammatory processes. This inflammatory response can precipitate myocardial injury, disrupt normal cardiac function, provoke arrhythmias, and, in severe cases, progress to heart failure or sudden cardiac death. Clinically, patients may present with chest pain, unexplained fatigue, dyspnea, palpitations, and peripheral edema. Prompt identification of these symptoms is essential, as early intervention may limit irreversible cardiac damage and reduce the risk of long-term sequelae.

Diagnostic evaluation typically involves laboratory assessment of cardiac biomarkers, electrocardiography, echocardiography, advanced imaging such as cardiac MRI, and, in select cases, endomyocardial biopsy to ascertain the etiology and extent of myocardial inflammation.

Management is tailored to the underlying cause and clinical severity. Therapeutic approaches may include anti-inflammatory agents, immunosuppressive therapy, antiviral medications, and standard treatments for heart failure, such as beta-blockers, ACE inhibitors, and diuretics. In fulminant or refractory cases, mechanical circulatory support or even heart transplantation may become necessary. Comprehensive management also incorporates lifestyle modification, vigilant monitoring, and early intervention to optimize patient outcomes and preserve cardiac function. Recent advances in cardiac imaging, biomarker discovery, and targeted therapies have refined diagnostic accuracy and individualized treatment strategies. Through integrated assessment and personalized care, clinicians are now better equipped to manage myocarditis and inflammatory heart disease, thereby mitigating complications and enhancing long-term cardiovascular health.